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ABSTRACT
Arsenic exposure constitutes one of the most
widespread environmental carcinogens, and is
associated with increased risk of many different
types of cancers. Here we report that arsenite
(As[III]) can induce both replication-dependent
DNA double-strand breaks (DSB) and homologous
recombination (HR) at doses as low as 5 mM
(0.65mg/l), which are within the typical doses often
found in drinking water in contaminated areas.
We show that the production of DSBs is dependent
on active replication and is likely to be the result
of conversion of a DNA single-strand break (SSB)
into a toxic DSB when encountered by a replication
fork. We demonstrate that HR is required for the
repair of these breaks and show that a functional
HR pathway protects against As[III]-induced cyto-
toxicity. In addition, BRCA2-deficient cells are sen-
sitive to As[III] and we suggest that As[III] could be
exploited as a therapy for HR-deficient tumours
such as BRCA1 and BRCA2 mutated breast and
ovarian cancers.
INTRODUCTION
Arsenic is considered to be a signiﬁcant hazard in our
environment and chronic exposure has been linked
to skin, lung, urinary bladder, kidney and liver cancer
(1–6). The primary route of exposure is via contaminated
drinking water. In some areas of the world contaminated
water levels can be up to several thousand times the WHO
maximum safe level of 0.01mg/l. In West Bengal, India,
the concentration of arsenic in contaminated water ranges
from 0.05 to 1.055mg/l (7). Arsenic occurs commonly in
the earth’s crust but rarely in its pure elemental state. It is
usually found in the form of highly toxic and unstable
sulphides, oxides and arsenates of potassium, sodium or
calcium. Once ingested inorganic arsenic is processed
through successive oxidative methylation and reduction
steps to its trivalent and pentavalent mono- and dimethy-
lated metabolites (8). The increased cancer risk posed by
contaminated water is thought to be due to the presence of
inorganic trivalent arsenite (As[III]+) (9), although later
reports have shown that the trivalent methylated metabo-
lites MMA[III] and DMA[III] are just as, if not more,
toxic (10). Arsenic trioxide has also been used as a che-
motherapeutic against certain cancers for example chronic
myeloid leukaemia (11,12). In this respect, arsenic resem-
bles several other anti-cancer drugs that as well as being
able to treat cancers are also able to induce cancer them-
selves. A common feature of carcinogenic anti-cancer
drugs is that many of them result in DNA damage; a
low dose results in mutations and cancer, and a high
dose causes toxicity and cell death.
Many mechanisms have been suggested for the carcin-
ogenic eﬀects of arsenic, including inhibition of the DNA
repair enzymes involved in nucleotide excision repair and
base excision repair (13–15), induction of DNA–protein
adducts and oxidative damage (16–20), altered DNA
methylation (21,22), increased cell proliferation through
changes in the expression of a number of genes associated
with cell growth (such as c-fos, c-jun and EGR-1) as well
as cell-cycle arrest [such as GADD153 and GADD45
(23)], p53 suppression (24,25) and p53 activation (26,27).
Here we investigate in more detail the type of DNA
lesions formed by arsenic. We ﬁnd that doses as low as
5 mM produce DNA double-strand breaks (DSBs) that
can be repaired when As[III] is removed. We show that
As[III] induces homologous recombination (HR), the
pathway known to play an important role in repair of
the replication associated DSBs. Furthermore, when com-
pared to wild-type, HR-deﬁcient cell lines were more
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sensitive, exhibited greater numbers of DSBs and under-
went increased apoptosis upon As[III] treatment. DSBs
were not induced in the absence of replication, suggesting
that they result from replication fork collapse. Together
these results suggest that HR plays an important role
in preventing As[III]-induced tumourigenesis and suggest
a potential therapeutic use for As[III] in the treatment of
HR-deﬁcient tumours.
MATERIALS AND METHODS
Chemicals and treatment conditions
Sodium meta-arsenite (NaAsO2) (As[III]) >99% purity
was purchased from Sigma-Aldrich (Gillingham, UK).
All treatments were performed in Dulbecco’s modiﬁed
Eagle’s Medium (DMEM) with 10% foetal bovine
serum and penicillin (100U/ml) and streptomycin sul-
phate (100mg/ml) at 378C under an atmosphere containing
5% CO2.
Cells and cell culture
The AA8, V79-4, irs1SF (28), V3-3 (29), EM9 (30), PXR3
(31), irs1 (32) and irsX2.2 (33) cell lines were provided
by Larry Thompson (Livermore, CA). Malgorzata
Zdzienicka generously provided the V-C8 and V-C8+B2
cell lines (34). All cell lines in this study were grown
in DMEM with 10% foetal bovine serum and penicillin
(100U/ml) and streptomycin sulphate (100 mg/ml) at 378C
under an atmosphere containing 5% CO2. SPD8 cells were
maintained in 5 mg/ml 6-thioguanine (6TG) to suppress
spontaneous reversion.
Recombination assay
A total of 1.5 106 SPD8 cells were inoculated into 100mm
dishes, in media without 6TG, 4 h prior to a 24 h treatment
with As[III]. After treatments, the cells were rinsed three
times with PBS and 10ml media added before allowing the
cells to recover for 48 h. After recovery, cells were released
by trypsinisation and counted. HPRT+ revertants were
selected by plating 3 105 treated cells per dish in the pres-
ence of HaST (50mM hypoxanthine, 10 mM L-azaserine,
and 5 mM thymidine). To determine cloning eﬃciency,
two dishes were plated with 500 cells eachwithout selection.
The colonies obtained were stained with methylene blue in
methanol (4 g/l), following 7 days (in the case of cloning
eﬃciency) or 10 days (for reversion) of incubation.
Reversion/recombination frequency=number of rever-
tants/(3 300000) cloning eﬃciency.
Immunofluorescence
Cells were plated onto coverslips allowed to settle for
4 h and grown for 24 h in the presence or absence of treat-
ments as indicated. Medium was then removed and cover-
slips rinsed once in PBS at 378C. Cells were ﬁxed in 3%
paraformaldehyde in PBS containing 0.1% Triton X-100
for 20min at room temperature and coverslips then exten-
sively washed (2 15min in PBS containing 0.1% Triton
X-100 and 0.15% bovine serum albumin, 1 10min in
PBS containing 0.3% Triton X-100 and 1 15min in
PBS containing 0.1% Triton X-100 and 0.15% bovine
serum albumin) prior to incubation with rabbit polyclonal
anti Rad51 antibody (H-92, Santa Cruz) or rabbit poly-
clonal anti gH2AX (Cell Signalling) at a dilution of 1:1000
for 16 h at 48C. The coverslips were subsequently washed
(as above) followed by 1 h incubation at room tempera-
ture with Cy-3-conjugated goat anti-rabbit IgG antibody
(Zymed) at a concentration of 1:500 and ﬁnally washed
again as above. Coverslips were washed brieﬂy in PBS,
DNA stained with 1 mg/ml To Pro (Molecular Probes)
and ﬁnally mounted in SlowFade Antifade (Molecular
Probes).
Images were obtained with a Zeiss LSM 510 inverted
confocal microscope using planapochromat 63/NA 1.4
oil immersion objective and excitation wavelengths 488,
546 and 630 nm. Through focus maximum projection
images were acquired from optical sections 0.50mm
apart and with a section thickness of 1.0 mm.
The frequencies of cells containing Rad51 foci were
determined in three separate experiments. At least 300
nuclei were counted on each slide. Nuclei containing
more than 5 foci were classiﬁed as positive.
Clonogenic survival assay
Five hundred cells were plated in triplicate onto 100mm
dishes 4 h prior to treatment with increasing doses of arse-
nic or MMS as indicated. 10 days later, when colonies
could be observed, they were ﬁxed and stained with
methylene blue in methanol (4 g/l). Colonies consisting
of more than 50 cells were subsequently counted. Each
colony was assumed to represent one cell surviving
from the original 500 and surviving fraction for each
dose calculated. Lines of best ﬁt were plotted and IC50
values determined. For survival in the presence or absence
of aphidicolin 500 cells plated the day before were pre-
treated for 1 h with 3 mM aphidicolin, then exposed to
200 mM arsenic in the presence or absence of 3 mM aphi-
dicolin for 6 h. Plates were then washed and normal media
left on the cells for 10 days. Colonies were stained and
counted as above.
Pulsed field gel electrophoresis
A total of 1.5 106 cells were plated onto 100mm dishes
and allowed 4 h for attachment. Exposure to arsenic with
or without 3 mM aphidicolin at the indicated dose was for
24 h after which cells were trypsinsied and 106 cells melted
into each 1% agarose insert. These inserts were incubated
in 0.5M EDTA, 1% N-laurylsarcosyl, proteinase K
(1mg/ml) at room temperature for 48 h then washed
four times in TE buﬀer prior to loading onto a 1% agar-
ose (chromosomal grade) gel. Separation by Pulsed-ﬁeld
gel electrophoresis was for 24 h (BioRad; 1208 angle, 60 to
240 S switch time, 4V/cm). The gel was subsequently
stained with ethidium bromide for analysis or transferred
to Hybond N+ transfer membrane (Amersham, UK) and
Southern blotting was carried out using [a-32P]dCTP-
labelled fragmented total genomic DNA the as a probe.
For repair assays agarose inserts were left for increasing
lengths of time in media prior to transfer to the EDTA/
laurylsarcosyl/proteinase K buﬀer.
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Annexin-V assay
A total of 1 105 cells were washed in PBS before for
staining using ApoTarget Annexin-V kit (Biosource
International) according to manufacturer’s instructions.
Brieﬂy, cells were mixed with FITC conjugated Annexin-
V protein to assay apoptosis and PI to assay cell viability.
Samples were analysed by ﬂow cytometry (Becton-
Dickenson FACSort, 488 nm laser) and percentage of
apoptotic cells determined as the fraction of live cells
(those that excluded PI) that had Annexin-V bound.
RESULTS
Arsenic has been shown to induce many types of DNA
damage including oxidative adducts, DNA strand breaks
and DNA-protein cross links (16,35), however, the mech-
anism by which each lesion is formed is not clear. Here
we used the Chinese hamster ovary cell line, AA8, to look
for As[III]-induced DNA damage. gH2A.X forms foci
upon DNA damage and is often taken as a marker of
DNA DSBs. We saw that doses as low as 5 mM As[III]
could induce gH2A.X foci (Figure 1B), while by 50 mM a
large increase can be seen (Figure 1A and B). It is not clear
exactly which types of damage induce gH2A.X foci so we
used pulsed ﬁeld gel electrophoresis (PFGE) to look
directly at DSB formation (36). By conventional ethidium
bromide staining DSBs were not detectable until
25–50 mM As[III] (Figure 1C), however, by Southern ana-
lysis, DSBs could be visualized at doses as low as 5 mM
(0.65mg/l), which is less than two orders of magnitude
above the WHO safety level (Figure 1C). It is estimated
that 50 mM As[III] produces a similar amount of DSBs as
a 6Gy dose of ionizing radiation (Figure 1D).
To study if As[III]-induced DSBs could be repaired
after release from the drug, we followed the disappearance
of DSBs by PFGE at diﬀerent time points after 24 h of
treatment with 50 mMAs[III] (Figure 1E). Repair occurred
between 2 h and 12 h after removal of As[III]. These
results indicate that As[III] induces DSBs that are repaired
in wild-type cells.
DSBs are substrates for the DSB-repair machinery,
including non-homologous end joining (NHEJ) and
homologous recombination (HR) (37). To investigate
if HR is triggered by As[III] we looked for Rad51 foci
formation. RAD51 is involved in the strand transfer reac-
tion of HR (38) and relocates into stable nuclear foci
during HR repair (39,40). We saw that 24 h of treatment
with 10 mMAs[III] could increase the number of cells con-
taining Rad51 foci 3-fold over spontaneous levels
(Figure 2A). To test directly whether As[III] can induce
HR we used the SPD8 cell line described previously (41).
Here, a partial duplication of exon 7 of the hypoxanthine
guanine phosphoribosyl transferase (hprt) gene that arose
spontaneously in SPD8 cells, leads to expression of non-
functional HPRT protein and reversion to wild type by
homologous recombination can be selected for in HaST
media. Colonies formed following selection are therefore
indicative of HR. We found a dose-dependent increase
in HR in the hprt gene when SPD8 cells were treated
with As[III] (Figure 2B). In this system, following a 24 h
treatment with 20 mM As[III] there was a 5-fold induction
in HR compared to spontaneous levels.
As DSBs and HR are induced following As[III] treat-
ment, it seems likely that HR is responsible for repair of
As[III]-induced DSBs. To test this we investigated the
level of As[III]-induced DSBs in the BRCA2-deﬁcient
cell line V-C8. BRCA2 is involved in regulating
Rad51 mediated HR (42) and thus these cells are HR
deﬁcient. Consistent with a role in repair we saw that
BRCA2-deﬁcient cells had higher levels of DSBs than
BRCA2 complemented (V-C8 B2) cells (Figure 3A). In
the V-C8 cells breaks were visible by ethidium bromide
staining at 1 mM As[III], 50 fold less As[III] than is
needed to produce a similar amount of DSBs in the
BRCA2 complemented cells. In addition DSBs were
examined 24 h after removal of As[III]. As expected
repair had occurred in BRCA2 complemented cells, but
in the BRCA2-deﬁcient cells breaks were still present
(Figure 3B), conﬁrming that HR is responsible for a por-
tion of DSB repair following As[III]-induced damage.
The persistence of DSBs can lead to apoptosis; therefore
we compared apoptosis in V-C8 and V-C8 B2 cells.
Following 24 h treatment with 10 mM As[III], V-C8 cells
were undergoing signiﬁcant levels of apoptosis compared
to both untreated and As[III]-treated V-C8 B2 cells
(Figure 3C and D). Together these data suggest that
As[III] induces DNA DSBs, which are repaired by HR
in wild-type cells.
Considering the high level of As[III]-induced apoptosis
in the BRCA2 defective cells we tested the possibility that
As[III] could be used to selectively kill HR-deﬁcient cells.
HR defective cell lines containing mutations in BRCA2
(V-C8) XRCC2 (irs1) and XRCC3 (irs1SF) were exam-
ined for their survival in increasing doses of As[III] rela-
tive to parental (V79-4 and AA8) and corrected cell lines
(V-C8 B2, irSX2.2 and PXR3) (Figure 4A, B and C).
BRCA2, XRCC2 and XRCC3-deﬁcient cell lines were
all sensitive to As[III]-induced cytotoxicity. A small
number of DSBs were repaired even in the V-C8 cell
line (Figure 3B). So to determine whether an alternative
pathway for DSB repair – non-homologous end joining
(NHEJ), is also involved in repair of As[III]-induced
DSBs, we determined the survival of the DNA-PK-deﬁ-
cient cell line (V3.3) in As[III] relative to the parental
(AA8) and DNA-PK complemented [V3.3(hYAC)] cell
lines. Unlike the HR-deﬁcient cells the DNA-PK-deﬁcient
line showed only a small increase in sensitivity to As[III],
suggesting that NHEJ has less of a role in repairing DNA
DSBs induced by low doses of As[III]. Interestingly there
was a diﬀerence in sensitivity at higher doses. Taken
together these results suggest HR is required for repair
of As[III]-induced DNA damage. The speciﬁc sensitivity
of HR-deﬁcient cell lines to As[III] opens up the possibil-
ity that As[III] may have potential therapeutic value in the
treatment of HR-deﬁcient tumours.
DNA double strand breaks can arise indirectly when the
replication fork reaches a single strand break or lesion,
and causes replication fork collapse (43–47). As[III] has
been reported to induce oxidative damage in cells
(16,19,48), which could potentially collapse replication
forks. We therefore determined whether or not replication
Nucleic Acids Research, 2009, Vol. 37, No. 15 5107
is required for As[III]-induced DSBs. Cells were co-treated
with As[III] and the DNA polymerase inhibitor aphidico-
lin and DSBs measured by PFGE (49). Less As[III]-
induced DNA DSBs were released on pulsed-ﬁeld gel
electrophoresis when cells were co-treated with aphidicolin
(Figure 5A). This suggests that As[III] may act by increas-
ing the number of lesions that collapse replication forks
during replication. We looked to see if inhibiting replica-
tion during exposure to As[III] could protect from As[III]-
induced death. AA8 cells were treated for 16 h
with increasing doses of As[III] in the presence or absence
of aphidicolin and apoptosis determined by Annexin V
staining (Figure 5B). As expected higher doses of As[III]
induced apoptosis. Treatment with aphidicolin alone
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also induced apoptosis but this level was not further
increased when As[III] was added. In addition, cells were
treated in the presence or absence of aphidicolin for 6 h
with a concentration of As[III] known to be toxic to wild-
type cells. They were then replated as for a colonogenic
survival assay (Figure 5C). A similar result was found,
aphidicolin alone was detrimental to cell survival but addi-
tion of arsenic did not cause any further decrease in cell
survival. These data together suggest that following expo-
sure to As[III] it is the collapse of replication forks and
resultant DSBs which are lethal to cells.
Many reports describe oxidative DNA damage as a
result of As[III] exposure (16–20). During repair of oxida-
tive base damage SSBs are induced and these can collapse
replication forks into DSBs (50). As As[III]-induced DSBs
were dependent upon DNA replication, we reasoned that
As[III] is inducing single strand lesions. To test this we
determined whether or not cells lacking the SSB repair
pathway were sensitive to As[III]. The EM9 CHO cell
line is deﬁcient in XRCC1 (30) and thus in SSB repair.
Surprisingly, in a colony forming assay with increasing
doses of As[III], EM9 cells showed similar cytotoxicity
as the parental AA8 cell line (Figure 5D). In addition,
we treated cells with As[III] and tested sensitivity to
the alkylating agent methyl methanesulfonate (MMS).
Co-treatment with As[III] increased the MMS sensitivity
of AA8 but not EM9 cells (Figure 5E). These data
together suggest that As[III] also inhibits repair of lesions.
It is likely that it is this increase in unrepaired lesions that
leads to replication fork collapse and DSB formation.
DISCUSSION
The way in which As[III] either directly induces DNA
damage and/or modiﬁes repair is predicted to play a
major role in the molecular mechanism of As[III]-induced
carcinogenicity. The DNA lesions that result following
As[III] exposure and the processes by which cells deal
with them are therefore of interest. The micromolar
concentrations of As[III] used in this study are similar to
the average arsenic level in whole blood of individuals
exposed to contaminated water (51,52). Therefore we
believe these experiments replicate the eﬀects that occur
in patients exposed to damaging levels of As[III].
We saw that, relative to wild-type cells, the SSB repair
(XRCC1)-deﬁcient EM9 cell line was not sensitive to
As[III] and suggest that this is because As[III] itself inhib-
its single strand break repair. This is supported by the
ﬁnding that, when co-treated with As[III], wild type but
not SSB repair-deﬁcient cells showed increased sensitivity
to the alkylating agent MMS. Our data are consistent with
previous ﬁndings that As[III] inhibits SSB repair to pre-
vent repair of oxidative damage (15,53). We also demon-
strate that DSBs are induced upon expose to As[III], even
at low and physiologically relevant doses. The appearance
of As[III]-induced DSBs was dependent on replication
therefore it is likely that As[III] does not directly induce
DSBs. Rather we propose that they arise as a result of
unrepaired SSBs at replication forks collapsing into
DSBs (47).
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The lack of increase in sensitivity to As[III] in SSB
repair-deﬁcient cells was surprising as As[III] is known
to generate reactive oxygen species (ROS) and is reported
to induce oxidative damage (54). However, our data
do not exclude such damage being induced and are com-
patible with a model whereby As[III] can both increase
damage and inhibit repair. Furthermore, As[III] has also
been shown to inhibit nucleotide excision repair (16,48).
It is therefore likely that As[III] targets many aspects of
DNA repair adding weight to the hypothesis that As[III]
mediated inhibition of DNA damage repair contributes
to increased replication fork collapse and thus the DSBs
observed.
DSBs are lethal to cells and like other DSBs collapsed
replication forks are a substrate for homologous recombi-
nation (47). We suggest that due to As[III]-induced
inhibition of repair, larger numbers of SSBs persist into
S-phase and collapse replication forks forming DSBs,
which can be the substrate for homologous recom-
bination. This explains the increase in Rad51 foci and
induction of HR seen following As[III] treatment. As
replication fork associated DSBs are repaired by HR
and mainly produce SCE events (47) this model would
explain the increased SCE levels in lymphocytes from
people exposed to Arsenic contaminated water (55,56).
We found that cells with a deﬁciency in HR [irs1, irs1SF
and V-C8, deﬁcient in XRCC2 (32), XRCC3 (28) and
BRCA2 (34)] were hypersensitive to As[III]-induced
damage and could not repair As[III]-induced DSBs,
implicating HR in the repair of these lesions. Gene poly-
morphisms in the HR gene XRCC3 were seen to inﬂuence
micronuclei (MN) frequency in human peripheral blood
lymphocytes of workers exposed to inorganic arsenite
compounds (57) and the DNA repair capacity was
reduced in arsenic exposed individuals developing
pre-malignant hyperkeratosis compared to exposed indi-
viduals without skin lesions (58). HR may then be impor-
tant in protecting against As[III]-induced carcinogenesis
and diﬀerences in HR capacity in individuals may con-
tribute to their risk following exposure.
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Figure 5. As[III] inhibits single-strand break repair, which causes replication forks to collapse and DSBs to form. (A) Ethidium bromide staining of
DNA double-strand breaks visualized with pulsed-ﬁeld gel electrophoresis after a 6-h treatment of AA8 cells with and without 3 mM aphidicolin
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Interestingly arsenic derived compounds have been used
for centuries in Chinese medicine to treat cancer and have
recently been used to eﬃciently treat acute promyelocytic
leukaemia (59) and several solid tumours (60). Arsenic
trioxide is well tolerated and the adverse reactions can
be managed (59). We have previously shown that PARP
inhibitors can be used alone to speciﬁcally kill HR-
deﬁcient tumours (61), they have also been used to sensi-
tise cells to other DNA damaging agents (62). Here we
show that BRCA2-deﬁcient cells are sensitive to As[III].
It is therefore possible that arsenic derived compounds
could be used as chemotherapeutic agents either alone
or in combination with other agents for this subset of
tumours. Arsenite is reported to compete with Zn in bind-
ing to the zinc ﬁnger of PARP1 in order to inhibit repair
of oxidative base damage (53). It can be predicted than
that As[III] prevents PARP from binding to damaged
DNA, this is diﬀerent to other PARP1 inhibitors currently
in clinical trials for treatment of BRCA1/2-associated
cancer, which are based on NAD analogues and inhibit
the enzymatic action of PARP1. Resistance to PARP
inhibitors in cell lines appears to occur via intragenic
deletion in BRCA2 (63), however other mechanisms of
resistance are possible and inhibiting PARP in a diﬀerent
way may provide a second route of treatment.
Only at concentrations greater than 20 mM did DNA-
PK-deﬁcient cells become sensitive to As[III], suggesting
that at higher doses As[III]-induced damage is repaired by
the error prone process of non-homologous end joining.
This could then explain the increased level of chromo-
somal aberrations seen in As[III] exposed individuals.
Indeed some reports suggest that the level of chromosomal
damage in exposed individuals can be used to predict
future risk of cancer (64).
In conclusion, we ﬁnd that As[III] causes replication-
dependent repairable DSBs (probably as a result of
decreased single strand break repair) and that the HR
machinery is activated. HR-deﬁcient cells are highly sen-
sitive to As[III]-induced lesions suggesting that HR is an
important pathway for error-free repair of As[III]-induced
damage. We suggest that the HR repair pathway is impor-
tant in preventing As[III]-induced DNA lesions from
causing gene rearrangements or mutations that may
inactivate tumour suppressor genes or activate proto-
oncogenes and thereby cause cancer. In addition, we
suggest that arsenic-based therapy may be an eﬃcient
way to kill HR-deﬁcient cancers.
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